Oppenheimer analyst Christopher Glynn downgraded Emerson (EMR) to Perform from Outperform without a price target The firm shuffled ratings in the industrials group. It cites valuation for the downgrade of Emerson. The company’s growth prospects are now reflected in the stock’s valuation, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: